Chinese Contaminant Was Inexpensive Heparin Mimic – U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA has identified the contaminant found in heparin linked to hundreds of adverse events as synthetically altered over-sulfated chondroitin sulfate, the agency announced during a March 19 conference call
You may also be interested in...
FDA Launches First Overseas Office In Beijing
Eight FDA staffers in three offices face language, volume challenges watchdogging 500 plus Chinese firms exporting drug components to the U.S.
U.S. FDA Launches First Overseas Office in Beijing
U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress
FDA Launches First Overseas Office In Beijing
Eight FDA staffers in three offices face language, volume challenges watchdogging 500 plus Chinese firms exporting drug components to the U.S.